DPP4 and dementia: However, we have discussed that, on one hand, there is a large and growing body of well-conducted observational studies that consistently report a significant association between SGLT2 inhibitor use and a reduced risk of all-cause dementia when compared with other antidiabetic agents such as sulfonylureas, metformin, GLP-1 RAs, and DPP-4 inhibitors.